|Intrexon Corporation -- USA Stock|| |
USD 12.26 0.93 7.05%
Founder and Chief Science Officer
Dr. Thomas D. Reed, Ph.D. is Founder, Chief Science Officer of Intrexon Corporationrationration. Dr. Reed cofounded Intrexon in 1998 and has served as Chief Science Officer since then and served on Intrexons board of directors until April 16, 2014. Dr. Reed is a molecular geneticist with over 20 years of experience in recombinant DNA technology. He has developed sophisticated transgenic model systems for studying the role of gene products in neuronal, cardiovascular, and cancer systems. Dr. Reed has published numerous peerreviewed articles in the fields of subcellular modulation, gene regulation and cardiac function and is an inventor on numerous patents
Age: 50 Founder Since 2016
301 556-9900 www.dna.com
Reed received his B.S. in Genetics from the University of CaliforniaDavis, an M.S. in Biological Science from Wright State University, and a Ph.D. in Molecular and Developmental Biology from the University of Cincinnati.
Thomas Reed Latest Insider Activity
The company has Return on Asset of (8.1) %
which means that on every $100 spent on asset it lost $8.1. This is way below average. In the same way, it shows return on shareholders equity (ROE)
of (21.17) %
meaning that it generated no profit with money invested by stockholders.
The company has 8.4 M in debt with debt to equity (D/E) ratio of 1.4 which is OK given its current industry classification. Intrexon Corporation has Current Ratio of 2.4 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.
Intrexon Corporationration operates in the synthetic biology field in the United States. Intrexon Corporation (XON) is traded on New York Stock Exchange in USA. It is located in VIRGINIA, U.S.A and employs 640 people. Intrexon is listed under Business Services category by Fama And French industry classification.